James Sims
Internal Medicine · Bellaire, TXNPI 1932183530
Payments from drug & device makers
Across 1,087 payments — averaging $3667.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$2.4M
- Viiv Healthcare Company$910K
- Gilead$549K
- Regeneron$64K
- Pfizer$53K
- AbbVie$12K
- plus $20K from 13 others
Across 18 payments — averaging $133.62 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$2K
- Viiv Healthcare Company$899
What the payments were for
- Consulting fees$7,98536%
- Speaking & faculty fees$980%
- Travel & lodging$3,57416%
- Food & beverage$10,33846%
- Education$2581%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 399 | $2,379,426 |
| Viiv Healthcare Company | 286 | $910,391 |
| Gilead | 286 | $548,939 |
| Regeneron | 15 | $64,349 |
| Pfizer | 16 | $52,657 |
| AbbVie | 19 | $11,572 |
| Theratechnologies Inc. | 12 | $11,318 |
| GSK | 1 | $4,434 |
| Boehringer Ingelheim | 1 | $2,230 |
| Janssen Products, LP | 5 | $456 |
| Napo Pharmaceuticals Inc | 17 | $380 |
| Johnson & Johnson(2 entities) | 19 | $283 |
| Sanofi-aventis U.S. LLC | 3 | $226 |
| Janssen Scientific Affairs, LLC | 1 | $107 |
| EMD Serono, Inc. | 2 | $47 |
| VBI Vaccine (delaware) Inc. | 2 | $36 |
| Dynavax Technologies Corporation | 1 | $17 |
| Exact Sciences | 1 | $17 |
| Cumberland Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,986,900 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 382 | $1,546,534 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 205 | $755,648 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 94 | $454,572 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 92 | $340,432 |
| DovatoDolutegravir Sodium/Lamivudine | 108 | $330,169 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 61 | $239,061 |
| RukobiaFostemsavir Tromethamine | 21 | $193,962 |
| TivicayDolutegravir Sodium | 74 | $193,186 |
| CabenuvaCabotegravir/Rilpivirine | 28 | $183,853 |
| DescovyEmtricitabine/Tenofov Alafenam | 57 | $134,331 |
| OzempicSemaglutide | 81 | $82,112 |
| IsentressRaltegravir Potassium | 38 | $70,685 |
| JulucaDolutegravir/Rilpivirine | 20 | $67,589 |
| PrezcobixDarunavir/Cobicistat | 25 | $67,587 |
| MounjaroTirzepatide | 63 | $66,174 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Genvoya, Descovy | $548,939 | $2,021,298531 claims |
| Viiv Healthcare CompanyTriumeq, Dovato, Rukobia, Tivicay, Cabenuva | $910,391 | $1,724,407456 claims |
| Janssen Products, LPSymtuza | $456 | $454,57294 claims |
| Johnson & JohnsonPrezcobix, Complera, Invokana | $283 | $113,01150 claims |
| MerckIsentress, Januvia | $2,379,426 | $79,43051 claims |
| Boehringer IngelheimTradjenta, Combivent Respimat, Jardiance | $2,230 | $39,19965 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $4,434 | $32,71060 claims |
| Janssen Scientific Affairs, LLCPrezista | $107 | $26,74314 claims |
| PfizerEliquis | $52,657 | $20,07334 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Bellaire
- Francisco VelazquezBellaire$11.6M
- Jan BurgerHouston$47.3M
- Nitin JainHouston$33.2M
- Muhammad IrfanTomball$30.6M
- Aung NaingHouston$30.6M
- Robert BassSan Antonio$25.6M
- Preetesh JainHouston$19.5M
- Paolo StratiHouston$19.2M
- Hernan SalazarSan Antonio$18.5M
- Nicholas ShortHouston$17.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.